PacBio completes sale of short-read sequencing assets to Illumina (pacb.com)

• Net cash proceeds of $48.1 million from Illumina
• Illumina assumes liabilities, grants back non-exclusive license
• PacBio focuses on long-read sequencing, SPRQ-Nx chemistry launch

"PacBio announced the completed sale of select short-read sequencing intellectual property and related assets to Illumina for $48.1 million net cash. Illumina assumed certain liabilities and granted a non-exclusive license back to PacBio. The transaction, which closed January 30, 2026, refocuses PacBio on its long-read sequencing platform, including accelerating the SPRQ-Nx chemistry launch. CEO Christian Henry stated the move strengthens the balance sheet and sharpens strategic focus."